Mekinist (Trametinib) is a MEK inhibitor medication with anticancer activity. It has potential in order to inhibit MEK1 as well as MEK2. This drug is licensed together with the dabrafenib for treating adult patients with the unresectable or metastatic melanoma. Mekinist (Trametinib 2 mg) should be taken orally once daily with a full glass of water. Mekinist tablets should not be chewed or crushed. It should be consumed without food, at least 1 hour prior to or 2 hours after a meal and at a similar time each day, with either the morning or evening dose of dabrafenib 150 mg. Females who are able to become pregnant should use effective birth control during treatment with the mekinist 2 mg and for 4 months after stopping the treatment. Mekinist may be responsible for causing fertility problems in females. This could affect patients ability in order to become pregnant. Interact with your doctor if this is a concern for you. Do not consume this medicine if you are breastfeeding or carrying a plan to breastfeed. It may pass into your breast milk. You and your doctor should decide if you will consume the mekinist or breastfeed. Take this medication exactly as your healthcare provider instructed you to take it. Do not change or interrupt your dose unless your doctor tells you. If you forget or miss a dose, consume it as soon as you remember. Apart from this if you take too much Mekinist, call your doctor or walk out to the nearest hospital emergency room right away. MEKINIST should be stored in the refrigerator between 36°F-46°F (2°C-8°C). Do not freeze. Keep this medicine dry and away from the moisture as well as light. Mekinist is not considered cost-effective in combination with the dabrafenib for treating unresectable or metastatic melanoma. In India the mekinist cost is quite reasonable, which can be grabbed from any legitimately established pharmaceutical wholesaler company. Mekinist Medication Guide for patients